Correction: Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib

Bin Zhao; Hong Zhao

doi:10.18632/oncotarget.26577

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib

PDF | How to cite

Oncotarget. 2019; 10:254-254. https://doi.org/10.18632/oncotarget.26577

Metrics: PDF 1319 views | ?

Bin Zhao¹ and Hong Zhao^1,2

¹ Center for Scientific Research, The Second Affiliated Hospital & Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou, 325027, China
² Department of Medical Oncology, The Third Affiliated Hospital of Harbin Medical University, Harbin, 150081, China

Published: January 04, 2019

This article has been corrected: The correct author affiliation information is given below:

Hong Zhao^1,2

Original article: Oncotarget. 2017; 8:93813-93824. DOI: https://doi.org/10.18632/oncotarget.21217.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26577

Publication Alerts

Corrections:

Correction: Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib